Published 24th February 2017

New review of ctDNA liquid biopsies

Portfolio company Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, has announced the publication of a new review of the use of ctDNA as a liquid biopsy for cancer treatment in the journal Nature Reviews Cancer. The paper was co-authored by Inivata’s Chief Scientific Officer and Founder Nitzan Rosenfeld and Co-Founder and Clinical Advisor James Brenton.

The review, titled "Liquid biopsies come of age: towards the implementation of circulating tumour DNA", explores the potential of ctDNA in cancer diagnosis, treatment selection, and monitoring disease burden.

The authors conclude that liquid biopsies have demonstrated broad potential clinical utility across a range of applications.

Read the Inivata release

Access the paper (paywall)